Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.

Bioorganic & medicinal chemistry·2021

Same author

Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation.

European journal of pharmacology·2017

Same author

Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout.

Journal of medicinal chemistry·2016

Same author

Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice.

Journal of clinical and experimental hepatology·2015

Same author

Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.

ACS medicinal chemistry letters·2015

Same author

Phlorizin prevents electrically-induced ventricular tachyarrhythmia during ischemia in langendorff-perfused guinea-pig hearts.

Biological & pharmaceutical bulletin·2014

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

SGLT2 inhibitors: molecular design and potential differences in effect.

Masayuki Isaji¹

¹Kissei Pharmaceutical Co. Ltd, Central Research Laboratory, Nagano, Japan. masayuki_isaji@pharm.kissei.co.jp

Kidney International. Supplement

|March 2, 2011

Summary

Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer a novel approach to diabetes treatment by increasing glucose excretion. This review examines various SGLT2 inhibitors, their profiles, and their potential as effective antidiabetic drugs.

Related Experiment Videos

Last Updated: Jun 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

Nephrology
Endocrinology
Pharmacology

Background:

The kidney's role in glucose homeostasis involves sodium-glucose cotransporter-2 (SGLT2).
Dysregulation of glucose handling contributes to diabetes pathology.
SGLT2 inhibitors represent a new therapeutic class for managing diabetes.

Purpose of the Study:

To review the structure and evolving profiles of various SGLT2 inhibitors.
To compare the similarities and differences among developed SGLT2 inhibitors.
To discuss the future potential of SGLT2 inhibitors in diabetes treatment.

Main Methods:

Review of existing literature on SGLT2 inhibitors.
Analysis of clinical study data for SGLT2 inhibitors.
Comparative assessment of SGLT2 inhibitor characteristics (selectivity, efficacy, pharmacokinetics, safety).

Main Results:

SGLT2 inhibitors promote renal glucose excretion by blocking glucose reabsorption.
These agents lower plasma glucose levels independently of insulin, improving insulin resistance.
Diverse SGLT2 inhibitors exhibit varying profiles influencing their therapeutic positioning.

Conclusions:

SGLT2 inhibitors are a promising emerging class of antidiabetic drugs.
The characteristic profile of each SGLT2 inhibitor dictates its clinical application.
Further evaluation is needed to fully realize the potential of SGLT2 inhibition in diabetes management.